Tyrosine Randomised Controlled Trial in Anorexia Nervosa

• Conditions: Anorexia Nervosa; Mental Health - Eating disorders

• Registration Number: ACTRN12609000007235
• Lead Sponsor: Dr Kenneth Nunn

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-01-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: Female
• Target Recruitment: 34

Inclusion Criteria

Female adolescents with anorexia nervosa

Exclusion Criteria

males, children (< 12 years) and adults (18 years and over), those with current (or within 6 months) drug or alcohol abuse, use of dietary tyrosine (or other amino acid) supplements within the previous 12 weeks, medically unstable patients, those with concurrent severe medical or neurological illness and participants with Phenylketonuria (inability to convert phenylalanine to tyrosine) and participants requiring noradrenergic or combined noradrenergic medications

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eating disorders psychopathology as measured by the Eating Disorders Examination, child version (chEDE)[the chEDE will be administered at baseline and week twelve (completion of the study)]

Secondary Outcome Measures

Name	Time	Method
Cognitive function tests (including the Rey Complex Figure, Verbal Fluency, Tower of London, Stroop Test, Verbal Paired Associate Learning, Digit Symbol Coding, Visual Learning, Matching, Trail Making tests and Design Fluency)[the cognitive function tests will be administered at baseline and week twelve (completion of the study)]